We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Concentra Group (CON - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Concentra Group is a member of the Medical sector. This group includes 986 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Concentra Group is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CON's full-year earnings has moved 1.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CON has gained about 3.3% so far this year. At the same time, Medical stocks have lost an average of 3.3%. As we can see, Concentra Group is performing better than its sector in the calendar year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.3%.
The consensus estimate for Boston Scientific's current year EPS has increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Concentra Group belongs to the Medical Services industry, which includes 58 individual stocks and currently sits at #65 in the Zacks Industry Rank. On average, this group has lost an average of 2.4% so far this year, meaning that CON is performing better in terms of year-to-date returns.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 84-stock industry is currently ranked #152. The industry has moved +6.1% year to date.
Concentra Group and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Concentra Group (CON - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Concentra Group is a member of the Medical sector. This group includes 986 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Concentra Group is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CON's full-year earnings has moved 1.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CON has gained about 3.3% so far this year. At the same time, Medical stocks have lost an average of 3.3%. As we can see, Concentra Group is performing better than its sector in the calendar year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.3%.
The consensus estimate for Boston Scientific's current year EPS has increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Concentra Group belongs to the Medical Services industry, which includes 58 individual stocks and currently sits at #65 in the Zacks Industry Rank. On average, this group has lost an average of 2.4% so far this year, meaning that CON is performing better in terms of year-to-date returns.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 84-stock industry is currently ranked #152. The industry has moved +6.1% year to date.
Concentra Group and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.